Award
National Cancer Institute 5R01CA283402-03
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
Recipient
Not specified
Award Amount
$636,578.00
Ceiling
$636,578.00
Awarded
September 21, 2023
Identifier
5R01CA283402-03
This NIH/NCI funded project studies the combination of arginine depletion and chemotherapy in aggressive prostate cancers to assess safety and efficacy.
Description
The project involves a clinical trial and preclinical studies focusing on arginine metabolism in aggressive variant prostate cancers. It aims to evaluate the safety, efficacy, and immune effects of combining ADI-PEG20 with chemotherapy.